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Adjunctive Daptomycin Attenuates Brain Damage and Hearing Loss
More Efficiently than Rifampin in Infant Rat Pneumococcal
Meningitis
Denis Grandgirard,a Melchior Burri,a Philipp Agyeman,a,b and Stephen L. Leiba,c
Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Switzerlanda; Department of Pediatric Infectiology, Inselspital, University Hospital, Bern,
Switzerlandb; and Biology Division, Spiez Laboratory, Federal Office for Civil Protection, Spiez, Switzerlandc
Exacerbation of cerebrospinal fluid (CSF) inflammation in response to bacteriolysis by beta-lactam antibiotics contributes to
brain damage and neurological sequelae in bacterial meningitis. Daptomycin, a nonlytic antibiotic acting on Gram-positive bac-
teria, lessens inflammation and brain injury compared to ceftriaxone. With a view to a clinical application for pediatric bacterial
meningitis, we investigated the effect of combining daptomycin or rifampin with ceftriaxone in an infant rat pneumococcal
meningitis model.
Eleven-day-oldWistar rats with pneumococcal meningitis were randomized to treatment starting at 18 h after infection with
(i) ceftriaxone (100 mg/kg of body weight, subcutaneously [s.c.], twice a day [b.i.d.]), (ii) daptomycin (10 mg/kg, s.c., daily) fol-
lowed 15min later by ceftriaxone, or (iii) rifampin (20 mg/kg, intraperitoneally [i.p.], b.i.d.) followed 15min later by ceftriaxone.
CSF was sampled at 6 and 22 h after the initiation of therapy and was assessed for concentrations of defined chemokines and cy-
tokines. Brain damage was quantified by histomorphometry at 40 h after infection and hearing loss was assessed at 3 weeks after
infection. Daptomycin plus ceftriaxone versus ceftriaxone significantly (P< 0.04) lowered CSF concentrations of monocyte che-
moattractant protein 1 (MCP-1), MIP-1, and interleukin 6 (IL-6) at 6 h andMIP-1, IL-6, and IL-10 at 22 h after initiation of
therapy, led to significantly (P< 0.01) less apoptosis, and significantly (P< 0.01) improved hearing capacity. While rifampin
plus ceftriaxone versus ceftriaxone also led to lower CSF inflammation (P< 0.02 for IL-6 at 6 h), it had no significant effect on
apoptosis and hearing capacity. Adjuvant daptomycin could therefore offer added benefits for the treatment of pediatric pneu-
mococcal meningitis.
Acute bacterial meningitis in infancy and childhood is a severeillness with high mortality and morbidity. Long-term se-
quelae are frequent, especially in resource-poor regions of the
world (17, 53), and persist for decades, as shown in an Australian
study, which documented neurological sequelae (hearing loss, ep-
ilepsy, cognitive impairment, and educational problems) in sur-
vivors of childhood meningitis up to 12 years after infection (29).
Nowadays, Streptococcus pneumoniae is the most common etio-
logical agent of acute bacterial childhoodmeningitis besidesNeis-
seria meningitidis and is associated with a particularly high rate of
hearing loss and other neurological sequelae (16). In both autopsy
studies of human victims of bacterial meningitis (48) and experi-
mental models of pneumococcal meningitis (7, 22, 24, 28), corti-
cal necrosis and apoptotic cell death in the dentate gyrus of the
hippocampus are reproducible histopathologic correlates of neu-
rological damage. Furthermore, injury of neuronal and hair cells
in the cochlea, as documented in experimental pneumococcal
meningitis in rats (14, 32), has been identified as a morphological
correlate of hearing loss.
In our current understanding of the pathophysiology of pneu-
mococcal meningitis, the host-mediated immune response, trig-
gered by subcapsular components of bacteria, contributes sub-
stantially to brain damage (25, 34, 63). Bacterial components are
recognized bymembrane-bound host cell receptors, such as TLR2
and TLR4 (3, 33). Through signaling by MyD88 (1, 35), proin-
flammatory cytokines and chemokines are released, which in turn
induces leukocyte migration into the cerebrospinal fluid (CSF)
space (34). Activated leukocytes, predominantly neutrophils, re-
lease inflammatory mediators, including reactive oxygen species
(ROS) (42) and matrix metalloproteinases (43), which have both
been shown to contribute to brain damage.
While bacterial components are continuously released during
the natural course of pneumococcal meningitis, antimicrobial
therapywith expanded-spectrum cephalosporins (i.e., ceftriaxone
[CRO] and cefotaxime) results in rapid bacterial cell lysis and a
sudden release of large amounts of microbial components (46,
60). Thus, an overshooting host-mediated inflammatory reaction,
which contributes to brain damage, is elicited at the beginning of
the antimicrobial therapy.
Most currently investigated strategies to improve the outcome
in experimental meningitis models involve the inhibition of dif-
ferent steps of the host-driven inflammatory cascade.Matrixmet-
alloproteinase inhibition, reduction of reactive oxygen species by
antioxidants, and inhibiting mediators of apoptosis are possible
candidates for inhibiting host immune reaction in bacterial men-
ingitis (25). In clinical practice, only adjuvant use of the anti-
inflammatory corticosteroid dexamethasone has been shown to
be beneficial in adults with bacterial meningitis (4, 11) and in
childhood meningitis caused by Haemophilus influenzae type b
(38, 49), a pathogen that has virtually been eradicated in global
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regions that have implemented the corresponding vaccination.
Efficacy of dexamethasone therapy in children with pneumococ-
cal meningitis is disputed (11, 51). Also, the benefit of adjunctive
dexamethasone treatment in adults with bacterial meningitis has
been questioned by a meta-analysis of 2,029 individual patient
data (64) and recent clinical studies (52).
Furthermore, in experimental models of meningitis, dexa-
methasone has been shown to induce apoptosis in the dentate
gyrus (8, 58) and to increase learning impairments (41).
A promising approach to reduce inflammation early in the
cascade of events leading to the pathophysiology of bacterial men-
ingitis is the “soft killing” of bacteria (56), i.e., to minimize the
release of inflammatory bacterial compounds by using nonlytic
antibiotics. The twomost extensively studied nonbacteriolytic an-
tibiotics in experimental meningitis are daptomycin (DAP), a cy-
clic lipopeptide, which disrupts cell membrane function and cell
wall metabolism (6), and rifampin (RIF), which inhibits protein
synthesis by inhibition of the DNA-dependent RNA polymerase
(65). Both antibiotics reduce the release of bacterial cell compo-
nents or toxins in vitro (15, 59) and in vivo (59, 60). Several exper-
imental animal studies exploring the use of these nonlytic antibi-
otics in pneumococcal bacterial meningitis have demonstrated
their beneficial effects. Daptomycin has been shown to reduce the
inflammatory reaction and brain damage compared to ceftriax-
one in an experimental pneumococcal meningitis model in rats
(26, 27). Meanwhile, rifampin and clindamycin reduced the re-
lease of lipoteichoic acid and had a neuroprotective effect in an
experimental rabbit model of pneumococcal meningitis (9, 10).
Furthermore, pretreatment with rifampin 1 h prior to ceftriaxone
therapy limited the extent of brain injury (59), and the combina-
tion of daptomycin with ceftriaxone was shown to be more active
than vancomycin plus ceftriaxone (18) in experimental pneumo-
coccal meningitis in rabbits.
The primary aim of this study was to assess the potential ben-
efits of sequential use of nonlytic before lytic antimicrobial ther-
apy in experimental pneumococcal meningitis in an experimental
setting that more closely mimics the clinical situation with regard
to the interval between adjuvant and antibiotic therapy. In the
present study, daptomycin and rifampin, twowell-described non-
lytic antibiotics given 15 min before ceftriaxone, were compared
to ceftriaxonemonotherapy.We challenged the hypothesis that by
acting before ceftriaxone-induced lysis of bacteria, nonlytic anti-
biotics would limit the release of bacterial components and posi-
tively impact on the inflammatory reaction and outcome of in-
fected animals.
MATERIALS AND METHODS
Animal model of meningitis. All animal studies were approved by the
Animal Care and Experimentation Committee of the Canton Bern (li-
cense no. 26/07) and followed the Swiss national guidelines for the per-
formance of animal experiments. A well-characterizedmodel of infant rat
pneumococcal meningitis was used (27, 44). Eleven-day-old Wistar rats
(n  112; Charles River, Germany) were injected intracisternally (i.c.)
with 10l of saline containing log10 6.173 0.149 CFU/ml of Streptococ-
cus pneumoniae (clinical isolate of a serotype 3 strain). Eighteen hours
later, CSF samples were obtained by puncture of the cisterna magna and
were cultured quantitatively on sheep blood agar plates to document
meningitis. The number of bacteria in CSF was determined by plating
serial dilutions of 10 l of CSF on blood agar plates. Animals were ran-
domized to receive ceftriaxone (n  32; Rocephin, Roche Pharma; 100
mg/kg of body weight, subcutaneously [s.c.], twice a day [b.i.d.]), dapto-
mycin (n 42; Cubicin [kindly provided by Cubist Pharmaceuticals], 10
mg/kg, s.c., daily), or rifampin (n 38; Rimactan, Sandoz Pharmaceuti-
cals AG; 20 mg/kg, intraperitoneally [i.p.], b.i.d.). Fifteen minutes after
daptomycin or rifampin treatment, animals were treatedwith ceftriaxone.
The dosages of daptomycin, rifampin, and ceftriaxone used in this study
were within the range of those used in previously published work (26, 27,
55, 59). CSF was sampled 6 h (24 h postinfection [hpi]) or 22 h (40 hpi)
after treatment. A subset of the animals were sacrificed at 40 hpi by an
overdose of pentobarbital (100 mg/kg, i.p.) and subsequently perfused
with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS),
and brains were removed and fixed in PFA for subsequent histology.
Treatments were repeated for a total of 3 days in surviving animals. Three
weeks after infection, animals were tested for hearing.
Myeloperoxidase assay. Myeloperoxidase (MPO) is an enzyme spe-
cific for azurophil granules and represents 5% of the total cellular protein
of neutrophils (2).HereMPOwasmeasured inCSF samples as an index of
leukocyte influx. Five microliters of uncentrifuged CSF were resuspended
in 200 l HETAB solution (0.5% hexadecyltrimethylammonium bro-
mide in 100 mM potassium phosphate buffer [pH 6.0]) and repeatedly
submitted to 3 cycles of freeze-thawing, sonication, and centrifugation for
5 min at 10,000 g at 4°C. Supernatants were stored at80°C until use.
Assays were performed in triplicate by mixing 155 l of HETAB buffer
with 10 l of samples and 10 l of o-dianisidine (20 mg/ml in water) in a
96-well plate. The reaction was initiated by the addition of 25 l of 2 mM
hydrogen peroxide in water. Absorbance was measured at 450 nm every
30 s for 10 min at 37°C using the ThermoMax microplate reader (Molec-
ular Devices Inc., Sunnyvale, CA). The linear domain of the curve was
used to determine the increase in absorbance.MPO activity was expressed
in relative units corresponding to Vmax as determined using SOFTmax
PRO software version 3.1.2 (Molecular Devices Inc., Sunnyvale, CA).
Cytokine expression in the CSF.Microsphere-basedmultiplex assays
(Lincoplex; Millipore Corporation, Billerica, MA) were used to assess the
CSF concentrations of the following cytokines: interleukin 1 (IL-1),
IL-6, IL-10, IL-18, tumor necrosis factor alpha (TNF-), MIP-1, and
monocyte chemoattractant protein 1 (MCP-1). The choice of cytokines is
based on the results of previous studies with the experimentalmodel used.
The present study was not meant to explore an extensive panel of cyto-
kine/chemokine levels but to judge from the effect of the described ther-
apeutic modalities on the host inflammatory reaction known to occur in
the model. Depending on the amount of harvested material, CSF was
diluted 5- to 9-fold to a final volumeof 25l. Aminimumof 100 beads per
analyte wasmeasured using a Bio-Plex 200 station (Bio-Rad Laboratories,
Hercules, CA). Calibration curves from recombinant standards were cal-
culated with Bio-PlexManager software version 4.1.1 using a five-param-
eter logistic curve fitting. When cytokine concentration was below the
detection limit, an arbitrary value corresponding to the detection limit
provided by the manufacturer multiplied by the dilution factor of the
samples was used for statistical analysis. The lower detection limits (in
pg/ml) provided by the manufacturer were as follows: IL-1, 2.32; IL-6,
9.8; IL-10, 5.41; IL-18, 4.78; TNF-, 4.44;MCP-1, 3.81; andMIP-1, 1.94.
Histology and morphometry. PFA-fixed brains were cryopreserved
in 18% sucrose in PBS at 4°C overnight. Forty-five-micrometer-thick cor-
onal brain sectionswere used to evaluate neuronal injury of the cortex and
hippocampus as described in detail previously (20). The sections were
stained for Nissl substance with cresyl violet and used for all determina-
tions. Quantification of apoptotic nuclei in the hippocampal dentate
gyrus was performed as described previously (7). In brief, cells exhibiting
characteristic histomorphologic features of apoptosis were counted in 4
different slices spanning the hippocampus. Using a400 magnification,
three visual fields in each of the two blades (upper and lower) of the
dentate gyrus were inspected for the presence of cells showing morpho-
logical signs indicative of apoptosis (condensed, fragmented dark nuclei,
apoptotic bodies). The number of apoptotic cells in each visual field was
determined, and a mean value per animal was calculated from all in-
spected fields.
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For the measurement of cortical brain damage, the entire cortex was
evaluated for damage by using a systematic uniform random sampling
procedure, with a random start and a sampling frequency of 15 slices
throughout the brain. Stained sections were scanned, and the total and
damaged cortical surfaces identified by decreased density of neurons were
quantified by the software ImageJ. The volume of total cortex and the
volume of the damaged tissue were calculated using the Cavalieri method
(30), and cortical neuronal injury was expressed as the percentage of af-
fected cortex. Histopathological evaluations were done by investigators
who were unaware of the clinical, microbiologic, and treatment data for
the respective animal.
Audiometry. Auditory brainstem responses (ABR) were recorded in
response to click stimulations (presentation rate, 20 clicks/second) on
both ears of animals anesthetized with amixture ofmedetomidine hydro-
chloride (Dormitor, Orion Pharma; 1 mg/kg, i.p) and ketamine hydro-
chloride (Ketalar, Pfizer; 50 mg/kg, i.p.). Subdermal needle electrodes
were placed in the mastoid of the tested ear (active), at the vertex (refer-
ence), and in the cervical neck muscles (ground). The sound stimulus
consisted of 100-s square wave impulses synthesized digitally using Sig-
Gen software (Tucker-Davis Technologies System II), fed into a program-
mable attenuator and, after digital-to-analog (D/A) conversion, trans-
duced by a speaker (JBLmodel 2405H) located 4 cm from the pinna. ABR
were amplified (103), band-pass filtered between 100 Hz and 3 kHz
(Ithaco model 1201), and averaged (n  500) during a 12-ms window
using the data acquisition software BioSig (Tucker-Davis Technologies
System II). The intensity of the click stimulus was reduced from 110 to 0
dB sound pressure level (SPL) in 5 dB steps. The hearing threshold was
defined as the lowest intensity that induced the appearance of a visually
detectable first peak and an average from both ears calculated per animal.
RESULTS
Clinical parameters.No significant difference in survival was ob-
served between the different experimental groups. Three weeks
after infection, the survival proportions of rifampin-, daptomy-
cin-, and ceftriaxone-treated animals were 85%, 83%, and 87%,
respectively. As an index of disease severity, gain or loss in weight
was determined for the different experimental groups. Figure 1A
depictsweight changes recorded between the time of infection and
40 hpi. Interestingly, while no difference in weight change could
be observed between groups for the interval between infection and
treatment, statistically less weight loss was observed for the DAP
group when recorded between initiation of treatment and 40 hpi.
A decrease in CSF MPO activity at 24 h after infection was ob-
served in DAP-CRO-treated animals (35.8  30.1 relative units)
and RIF-CRO-treated animals (30.4  29.1) compared to CRO-
treated animals (49.8 37.0) without reaching statistical signifi-
cance, as determined by the Kruskal-Wallis test (P 0.1). At 40 h
after infection, no difference between the groups could be ob-
served.
Neuronal damage. Neuronal damage was examined on brain
sections of a subset of animals which were sacrificed 40 h after
infection. In the present study, only a moderate level of cortical
damage was noted across all treatment arms. Cortical damage was
present in 3 out of 12 CRO-treated animals, in 1 out of 15 DAP-
CRO-treated animals, and in none of 13 RIF-CRO-treated ani-
mals analyzed by histomorphometry. In affected animals, the ex-
tent of cortical damage was restricted to small focal areas, not
exceeding 2% of the total cortical volume. When comparing the
proportions of animals which develop cortical damage, significant
differences (P  0.0001, chi-square test) were found between
CRO (25%), DAP (7%), and RIF (0%).
A significant difference (P  0.01, Kruskal-Wallis) in the ex-
tent of apoptosis in the dentate gyrus of the hippocampus was
found between the different experimental groups. Apoptosis was
significantly reduced in DAP-CRO-treated animals (1.4  2.5
cells/visual field, n 15) compared either toCRO-treated animals
(5.6 6.8 cells/visual field, n 12; P 0.01,Mann-Whitney test)
or to RIF-CRO-treated animals (6.3  6.4 cells/visual field, n 
13; P  0.03). In contrast, no such difference was observed be-
tween RIF-CRO-treated and CRO-treated animals (Fig. 1B).
Hearing loss 3 weeks after infection. The loss of hearing ca-
pacity consecutive to pneumococcal meningitis was determined
by measuring the increase in the threshold of the stimulus neces-
sary to induce a detectable auditory brainstem response (ABR). In
the present experimental setting, the hearing threshold of healthy
animals was 30 to 35 dB SPL (data not shown). In infected CRO-
FIG 1 Weight loss (A), hippocampal apoptosis (B), and hearing loss (C)
under the 3 treatment regimens. (A) Statistically significant differences (P 
0.04, Kruskal-Wallis) in weight loss were observed at 22 h after initiation of
antibiotic therapy between groups. Pairwise comparison (Mann-Whitney
test) revealed significant differences between DAP-CRO versus CRO (P 
0.03) andDAP versus RIF-CRO (P 0.04). (B) Significantly less hippocampal
injury was observed in animals treated with DAP-CRO compared to both
RIF-CRO-treated (P 0.03) and CRO-treated (P 0.01) animals. No differ-
ence was observed between RIF-CRO and CRO. (C) Hearing loss was signifi-
cantly attenuated by DAP-CRO (P  0.01) in comparison to CRO, while
RIF-CRO versus CRO did not differ significantly (P NS).
Daptomycin and Ceftriaxone in Pneumococcal Meningitis
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treated animals, this threshold was increased to 75.3 21 dB SPL
(n  16). Significant differences in thresholds were found (P 
0.01, Kruskal-Wallis) by comparing the three experimental
groups. Hearing loss assessed by an increase in the hearing thresh-
old observed in CRO-treated animals was significantly attenuated
by DAP-CRO treatment (51.8  21.3 dB SPL, n  20; P  0.01,
Mann-Whitney). A trend for attenuation was also observed by
RIF-CROversus CRO treatment (60.8 21.7 dB SPL, n 20; P
0.054) (Fig. 1C).
Inflammatory reaction. Modulation of the inflammatory re-
action in response to antimicrobial therapy was analyzed by mea-
suring the CSF concentration of cytokines and chemokines at dif-
ferent time points following the initiation of antimicrobial
treatment. The DAP-CRO combination therapy resulted in lower
CSF concentration of cytokines/chemokines. Statistical signifi-
cance (Kruskal-Wallis) was reached forMIP-1,MCP-1, and IL-6
at 6 h after therapy (Fig. 2) and MIP-1, IL-6, and IL-10 at 22 h
after therapy (Table 1). For those cytokines/chemokines with sig-
nificant differences in CSF concentration, pairwise analysis
(Mann-Whitney) revealed a statistically significant difference for
the comparison of DAP-CRO versus CRO but not for RIF-CRO
versus CRO (except IL-6 at 6 h after therapy) or DAP-CRO versus
RIF-CRO.
DISCUSSION
Effective antimicrobial treatment of bacterial meningitis depends
on antibiotics that have a fast bactericidal effect on the meningitis
pathogen. For both childhood meningitis and pneumococcal
meningitis in adults, it was shown that a delay in CSF sterilization
leads to an adverse outcome; i.e., a higher incidence of neurologic
abnormalities, including moderate to profound hearing impair-
ments at the time of hospital discharge and follow-up (39) or
increased mortality (5).
The emergence of resistant bacterial strains, i.e., penicillin-re-
sistant pneumococci, is therefore of concern, as failure to cover for
these strains may lead to delayed sterilization of CSF. Although
most studies have not showndifferences in outcome between pen-
icillin-resistant and -susceptible strains (12, 19), failure related to
FIG 2 CSF concentrations of cytokines and chemokines in the 3 treatments of
experimental pneumococcalmeningitis at 6 h after initiation of therapy. Over-
all comparison between groups revealed statistically significant differences for
MCP-1 (P 0.028),MIP-1 (P 0.028), and IL-6 (P 0.014), as determined
by the Kruskal-Wallis test. Pairwise comparison between groups was signifi-
cant forDAP-CROversus CRO for all cases andRIF-CROversus CROonly for
IL-6 at 6 h after therapy.
TABLE 1 CSF cytokine/chemokine concentrations at 24 and 42 hpi (6 and 24 h after initiation of antibiotic therapy)b
Time
postinfection Cytokine/chemokine
Concn (pg/ml)a
Kruskal-Wallis
P valueCRO DAP-CRO RIF-CRO
24 hpi IL-1 174.7 (11.6–848.4) 67.75 (11.6–451.6) 80.25 (11.6–811.9) 0.32
IL-6 30,605 (9,127–97,523) 10,017 (3,369–48,270) 10,950 (1,727–40,143) 0.017
IL-10 878.7 (27.1–4,511) 27.1 (27.1–1,849) 418 (27.1–3,396) 0.22
IL-18 218.2 (23.9–511.6) 135.8 (23.9–3,170) 123 (23.3–1,035) 0.63
TNF- 141.6 (22.2–236.8) 91.1 (22.2–367.7) 150.1 (22.2–316.5) 0.72
MCP-1 14,366 (6,758–29,248) 9,337 (2,455–13,723) 11,801 (6,415–26,139) 0.028
MIP-1 393.1 (113.1–765.4) 181.6 (27.3–604.1) 256.8 (67.7–523.2) 0.028
42 hpi IL-1 70.46 (11.6–282.3) 11.6 (11.6–159.8) 48 (11.6–368.4) 0.069
IL-6 68.6 (49–415.5) 49 (49–88.2) 49 (49–88.2) 0.04
IL-10 37.9 (27.1–3,934) 27.1 (27.1–48.7) 27.1 (27.1–118.1) 0.005
IL-18 473.2 (33.5–2,600) 277.7 (47.1–3,425) 605.8 (23.9–2,193) 0.4
TNF- 30.6 (2.9–54.1) 19.7 (3.6–37.8) 22.2 (2–54.9) 0.45
MCP-1 1,088 (19.1–7,814) 1,213 (19.1–2,686) 1,238 (19.1–6,011) 0.94
MIP-1 37.7 (9.7–153.4) 9.7 (9.7–32.7) 11.1 (9.7–288.8) 0.012
a Concentrations expressed as median (minimum-maximum).
b Text is in bold when overall comparison between groups revealed statistically significant differences as determined by the Kruskal-Wallis test (P 0.05).
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this resistance has been observed and may be linked to a worse
clinical outcome (57) or increased mortality (5).
Modernmeningitis therapy with an expanded-spectrum ceph-
alosporin, including vancomycin in regions where penicillin-re-
sistant pneumococci pose a threat, fulfills these requirements well.
But on the downside, bacteriolytic action of these cell wall-active
substances additionally supports the host inflammatory reaction
andmay contribute to theworsening of the patient’s outcome (45,
47, 61). Therefore, strategies combining adequate antimicrobial
therapy with adjuvant therapies preventing the excessive host in-
flammatory reaction have been proposed to reduce neurological
damage and ameliorate the outcome in terms of mortality and
morbidity (46). It has been shown that the nonlytic antimicrobials
rifampin and daptomycin are promising candidates for the reduc-
tion of inflammation and brain damage in experimental pneumo-
coccal meningitis. For rifampin, it has been shown that it attenu-
ates inflammation and brain damage if given 1 or 6 h (versus 15
min in this study) before ceftriaxone (21, 59). Similarly, daptomy-
cin has been shown to be noninferior to ceftriaxone in experimen-
tal pneumococcal meningitis (18) and to reduce inflammation
and brain damage in this experimental setting (26, 27). Our work
adds to these studies by a head-to-head comparison of the two
nonlytic antimicrobial compounds in a study with a clinically ac-
ceptable interval of 15 min (an interval that is accepted for the
adjuvant administration of dexamethasone) between administra-
tion of the nonlytic antimicrobials and ceftriaxone. In addition,
this is the first study to report on the clinically relevant outcome of
hearing loss.
Animals in the daptomycin-ceftriaxone treatment armhad sig-
nificant lower CSF levels of the chemokinesMCP-1, MIP-1, and
IL-6 compared to ceftriaxonemonotherapy, a trend also observed
for the rifampin-ceftriaxone treatment arm, although only reach-
ing statistical significance for IL-6 at 6 h after the initiation of
therapy. This measurable reduction of the inflammatory reaction
in the daptomycin-ceftriaxone treatment arm also translated into
less cortical damage, less hippocampal apoptosis, and less hearing
loss compared to the ceftriaxone treatment arm. For animals in
the daptomycin-ceftriaxone treatment arm, a significant reduc-
tion inweight loss was noted compared to the other two treatment
arms. This is likely due to a decrease in the release of cytokines and
chemokines and subsequent reduction in systemic inflammation
(27, 60). Taken together, the present results are in accord with our
previous findings that daptomycinmonotherapy leads to a reduc-
tion of proinflammatory cytokines and attenuation of neuronal
damage compared to ceftriaxone monotherapy in experimental
pneumococcal meningitis (26). Contrary to what has previously
been shown in a rabbit model of pneumococcal meningitis (59),
rifampin-ceftriaxone treatment was not effective in protecting
against hippocampal apoptosis. Differences in time-kill kinetics
between daptomycin and rifampin may explain the observed dif-
ference in neuroprotection since a beneficial effect by pretreat-
mentwith rifampinwas observed onlywith an interval of 1 and 6 h
before ceftriaxone administration (21, 59).
A significant decrease in hearing loss was observed in the dap-
tomycin-ceftriaxone treatment arm. Hearing loss during pneu-
mococcal meningitis may result in part from the production of
highly reactive oxygen species (ROS) (31). Treatment with rifam-
pin has been shown to decrease the level of ROS compared to
ceftriaxone in an experimental meningitis model in rabbits (9). In
this study, hearing loss was determined by audiometry 3 weeks
after infection. At that time, hearing loss is permanent, in contrast
to the early reversible form of hearing loss observed during the
acute stage of the disease in experimental models. The permanent
hearing impairment best finds its morphological correlate in the
reduction of spiral ganglion neuronal cells, which was not ob-
served until 48 hpi (32) and after damage to the hippocampus has
already occurred. Daptomycin-ceftriaxone may therefore protect
against hearing loss by reducing the production of ROS or by
influencing pathophysiological events occurring later than those
involved in hippocampal injury.
Overall, our study results favor sequential therapy with dapto-
mycin before standard meningitis therapy with ceftriaxone as an
alternative to treatment with rifampin-ceftriaxone or ceftriaxone
monotherapy. While daptomycin possesses potent in vitro bacte-
ricidal activity against most clinically relevant strains of Gram-
positive bacteria, including methicillin-resistant Staphylococcus
aureus, and vancomycin-resistant enterococci (13), it lacks any
activity against Gram-negative bacteria.
Although Streptococcus pneumoniae and Streptococcus agalac-
tiae have been shown to be the predominant species causingmen-
ingitis in a recent U.S. survey, Gram-negative bacteria, i.e., Neis-
seriameningitis andHaemophilus influenzae, still represent 20%of
all cases (62). Furthermore, Neisseria meningitis was responsible
for 80% of the meningitis burden in the “meningitis belt” of sub-
Saharan Africa during the 2010 epidemic (66). Therefore, for em-
pirical meningitis therapy, daptomycin would have to be com-
bined with a second antibiotic targeting Gram-negative bacteria,
e.g., an expanded-spectrum cephalosporin.
Anothermain issue to be considered in the treatment of central
nervous system infection is the difficulty to reach therapeutic an-
tibiotic concentrations in the CSF due to the limited permeability
of the blood-brain barrier. For daptomycin, it has been shown in a
rabbit pneumococcal meningitis model that penetration into the
CSF space is enhanced by the presence of inflamedmeninges (5%
versus 2% with noninflamed meninges) (23). The addition of
dexamethasone reduced the penetration of daptomycin into CSF
to 2% in the same experimental model (18). The CSF penetration
of rifampin in a similar experimental model was 3 to 5% and
seemed less affected by concomitant dexamethasone therapy (50).
More recently, in patients with suspected or confirmed neurolog-
ical infections, CSF penetrations of 0.8% (36) to 5% (54) were
documented for daptomycin. It has been proposed that the differ-
ences between these studies are due to the variations in the degree
of inflammation of the meninges. Furthermore, when the differ-
ences in protein binding betweenCSF and serumwere considered,
the CSF penetration of daptomycin increased to 11.5% (36). Suc-
cessful treatment of meningitis caused by vancomycin-resistant
enterococci (37) or methicillin-resistant Staphylococcus aureus
(40) have been reported using daptomycin at high doses (6 to 12
mg/kg) and/or in combination with gentamicin or linezolid.
These doses are higher than the doses currently approved for the
treatment of complicated skin and soft tissue infections (4mg/kg)
or S. aureus bloodstream infections (6 mg/kg), but higher doses,
such as those used for the treatment ofmeningitis, may still be safe
and well tolerated (67) and result in higher levels in the CSF.
In conclusion, our experimental data indicate that combining
the nonlytic antibiotic daptomycin with ceftriaxone in a 15-min
sequence may represent a beneficial strategy for the empirical
treatment of bacterial meningitis. By decreasing the host-driven
inflammatory reaction and by rapidly killing bacteria in the CSF
Daptomycin and Ceftriaxone in Pneumococcal Meningitis
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space, including strains resistant to other antibiotics, daptomycin-
ceftriaxonemay contribute to improved outcome of patients with
pneumococcal meningitis.
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